164 related articles for article (PubMed ID: 34205581)
1. Impact TMPRSS2-ERG Molecular Subtype on Prostate Cancer Recurrence.
Kobelyatskaya AA; Pudova EA; Snezhkina AV; Fedorova MS; Pavlov VS; Guvatova ZG; Savvateeva MV; Melnikova NV; Dmitriev AA; Trofimov DY; Sukhikh GT; Nyushko KM; Alekseev BY; Razin SV; Krasnov GS; Kudryavtseva AV
Life (Basel); 2021 Jun; 11(6):. PubMed ID: 34205581
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
Barwick BG; Abramovitz M; Kodani M; Moreno CS; Nam R; Tang W; Bouzyk M; Seth A; Leyland-Jones B
Br J Cancer; 2010 Feb; 102(3):570-6. PubMed ID: 20068566
[TBL] [Abstract][Full Text] [Related]
3.
Kobelyatskaya AA; Kudryavtsev AA; Kudryavtseva AV; Snezhkina AV; Fedorova MS; Kalinin DV; Pavlov VS; Guvatova ZG; Naberezhnev PA; Nyushko KM; Alekseev BY; Krasnov GS; Bulavkina EV; Pudova EA
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232996
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
6. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
Mavura Y; Song H; Xie J; Tamayo P; Mohammed A; Lawal AT; Bello A; Ibrahim S; Faruk M; Huang FW
Prostate; 2023 Apr; 83(5):395-402. PubMed ID: 36598071
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
10. The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
van Strijp D; de Witz C; Heitkötter B; Huss S; Bögemann M; Baillie GS; Houslay MD; Bangma C; Semjonow A; Hoffmann R
Prostate Cancer; 2019; 2019():8107807. PubMed ID: 31275657
[TBL] [Abstract][Full Text] [Related]
11. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
12. Status of
Bhanushali A; Rao P; Raman V; Kokate P; Ambekar A; Mandva S; Bhatia S; Das BR
Prostate Int; 2018 Dec; 6(4):145-150. PubMed ID: 30505817
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
15. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
18. SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo.
Cruz-Hernández CD; Cruz-Burgos M; Cortés-Ramírez SA; Losada-García A; Camacho-Arroyo I; García-López P; Langley E; González-Covarrubias V; Llaguno-Munive M; Albino-Sánchez ME; Cruz-Colín JL; Pérez-Plasencia C; Beltrán-Anaya FO; Rodríguez-Dorantes M
Cancer Cell Int; 2020; 20():312. PubMed ID: 32694934
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype.
Kobelyatskaya AA; Pudova EA; Katunina IV; Snezhkina AV; Fedorova MS; Pavlov VS; Kotelnikova AO; Nyushko KM; Alekseev BY; Krasnov GS; Kudryavtseva AV
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
